Thai Union Investment in Gelagen Opens Opportunities for Cooperation in Marine Collagen Raw Material Procurement, Development and Production
Thai Union is boosting its biotech business by investing in a UK startup that produces collagen from jellyfish. Gelagen is one of the leading biotech collagen companies headquartered in the UK. This investment will support his Gelagen’s growth as a future global leader in biomaterials and medical devices.
Thiraphong Chansiri, Chief Executive Officer of Thai Union Public Company Limited or TU said: Thai Union Group Public Company Limited announced that it has invested in the company, joining other strategic investors. British start-up Gelagen has raised a total of £8.7m (approximately Bt3.7bn-3.8bn) in its Series A funding round. This Thai Union investment was made through the company’s venture fund.
Gelagen, a medical biotechnology company, is developing collagen in the form of a biomaterial from jellyfish, with a mission to revolutionize regenerative medicine. Treatment focuses on restoring the body’s deterioration at the cellular level.
The funds will be used to accelerate the clinical development of proprietary collagen. Better properties than mammalian collagen. A new sustainable collagen biomaterial can be used to treat skin diseases as a biomaterial for tissue regeneration.
Thai Union’s investment in Gelagen will open opportunities for collaboration in raw material sourcing, manufacturing and future use in Thai Union’s existing and developed products.
“Forms of marine collagen can be used in pharmaceuticals, cosmetics, food and nutrition. Thai Union is looking forward to working together in research and development, including manufacturing plants around the world,” adds CEO Chansiri. .